CA-WETA-DIGITAL/AUTODESK
17.6.2021 15:02:07 CEST | Business Wire | Press release
Weta Digital, one of the world’s premiere visual effects studios, has partnered with global media and entertainment software provider, Autodesk, Inc. (NASDAQ: ADSK ), to launch WetaM - a ground breaking product offering that provides tools designed and developed by Weta Digital, fully embedded in Autodesk Maya. Weta Digital has won 13 Academy Sci-tech Awards for its tools that helped artists produce some of the most successful film and TV series in the world, including “The Lord of the Rings,” “Avatar,” “Game of Thrones,” and “Planet of the Apes,” to name a few. Weta intends to rollout WetaM as a private beta in Q4.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210617005301/en/
WetaM productizes Weta’s unique set of proprietary VFX tools for artists built on Maya’s open API, and will be commercialized by Weta Digital as a subscription cloud service. For the first time, artists from around the world will have access to one complete—from stage to screen—cloud based pipeline. The launch of WetaM marks the first product launch under a newly formed Software-as-a-Service (SaaS) division within Weta Digital. This new business arm is an integral part of Weta’s expansion strategy to offer professional and prosumer tools to artists across the global entertainment industry.
“WetaM is the first step in the democratization of VFX and animation production. Weta Digital brings together the most creative minds in the world and has been a pioneering innovator in the visual effects and entertainment industry for decades,” said Prem Akkaraju, CEO of Weta Digital. “WetaM is a transformational move that will raise the bar for global creative production, redefining the industry in the process. At its core, this partnership with Autodesk will extend the reach of the Weta magic, making it more accessible for artists in pursuit of creating amazing characters and worlds across film and television.”
“We are longtime fans of Weta’s remarkable visual effects achievements, and they are constantly breaking new ground building immersive, imaginary worlds and unbelievably real and engaging digital characters,” said Diana Colella, senior vice president, Entertainment & Media Solutions, Autodesk. “The debut of WetaM is a gamechanger as it opens up years of Weta’s dedicated animation and VFX R&D resources to all creatives. It is exciting to be working with Weta to bring their magic to Maya artists, offering them powerful new effects tools and time-saving automation capabilities.”
As a leader in VFX and animation for the last three decades, Weta Digital’s DNA is rooted in technological innovation, unmatched artistic talent and exceptional visual style. Brought to life through the partnership with Autodesk, WetaM shares this DNA and gives artists, everywhere, access to the unique visual design and pipeline efficiency tools that have driven Weta Digital’s Academy® Award-winning success.
ABOUT WETA DIGITAL
Weta Digital is the standard-bearer for creativity and innovation in visual effects and animation, attracting talent, partners, and clients that seek to push what is possible in pursuit of their artistic vision. Weta’s proprietary pipeline continues to evolve and provide artists with the tools they need to create their best work. Based in Wellington, New Zealand, Weta Digital is the largest single-site VFX studio in the world drawing artists from over 40 countries. They are some of the most creative and ambitious artists, engineers, and executives in entertainment and their work has earned six visual effects Academy Awards, ten Academy Sci-Tech Awards and six visual effects BAFTA Awards in addition to the 34 Visual Effects Society Awards awarded to them by their peers. Ground-breaking, performance-driven animated characters from Gollum to Caesar, and worlds from Middle-earth to Pandora, are regarded as some of the best visual effects ever to appear on screen.
For more information:
Weta Digital: www.wetafx.co.nz
Follow: @weta_digital
ABOUT AUTODESK
Autodesk makes software for people who make things. If you've ever driven a high-performance car, admired a towering skyscraper, used a smartphone, or watched a great film, chances are you've experienced what millions of Autodesk customers are doing with our software. Autodesk gives you the power to make anything. For more information, visit www.autodesk.com or follow @autodesk.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210617005301/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom